OTC Markets OTCQB - Delayed Quote USD

Altamira Therapeutics Ltd. (CYTOF)

0.0800

+0.0047

+(6.24%)

At close: April 29 at 3:32:47 PM EDT

Key Events

Advanced Chart

Loading Chart for CYTOF

Previous Close 0.0753
Open 0.0530
Bid 0.0620 x --
Ask 0.1149 x --
Day's Range 0.0530 - 0.1050
52 Week Range 0.0500 - 2.4700
Volume 28,617
Avg. Volume 12,393
Market Cap (intraday) 302,281
Beta (5Y Monthly) 2.71
PE Ratio (TTM) 0.04
EPS (TTM) 1.8200
Earnings Date Apr 30, 2025
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 5.80

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

altamiratherapeutics.com